Edition:
United States

Profile: CSL Ltd (CSL.AX)

CSL.AX on Australia Stock Exchange

114.60AUD
20 Jan 2017
Change (% chg)

$3.10 (+2.78%)
Prev Close
$111.50
Open
$111.92
Day's High
$115.99
Day's Low
$111.92
Volume
2,295,551
Avg. Vol
1,017,892
52-wk High
$121.25
52-wk Low
$91.62

CSL Limited is a biotherapeutics company that develops and delivers biotherapies. The Company's principal activities are research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. Its segments include CSL Behring, Seqirus and CSL Intellectual Property. The CSL Behring segment manufactures, markets and develops plasma therapies (plasma products and recombinants). The Seqirus segment manufactures and distributes non-plasma biotherapeutic products. Seqirus manufactures, sells and distributes a range of vaccines, antivenoms and other pharmaceutical products in Australia and New Zealand. It also manufactures and markets in vitro diagnostic products through Seqirus immunohematology. The CSL Intellectual Property segment is engaged in licensing of intellectual property generated by the Company to unrelated third parties. The Company has facilities in Australia, Germany, Switzerland, the United Kingdom and the United States.

Company Address

CSL Ltd

45 Poplar Rd
MELBOURNE   VIC   3052
P: +613.93891911
F: +613.93891434

Company Web Links